Short-Chain Fructooligosaccharide

Phase 1Small molecule

MMayo Clinic

Short-Chain Fructooligosaccharide is one of 18 small molecule programs targeting Pouchitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PouchitisActive, not recruiting

PouchitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Pouchitis

#DrugCompanyPhaseTrials

Tremfya

Johnson & Johnson

Approved

1 2

Cipro

Bayer

Approved

1 3

Victoza

Xifaxan

1 5

Flagyl

Monurol

Entyvio

2 8

Stelara

Johnson & Johnson

Phase 3

1 9

Humira

CCelltrion

Phase 3

1 10

Velsipity

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pouchitis1 trial

Study of Sc-FOS for Pouchitis Prevention

Completed·MMayo Clinic·Phase 1·NCT02203955·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Short-Chain Fructooligosaccharide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Short-Chain Fructooligosaccharide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Short-Chain Fructooligosaccharide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMayo Clinic

Short-Chain Fructooligosaccharide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pouchitis1 trial

References

Drug Info

Quick Facts

Related News